IL-23 Inhibitors in Psoriasis: A Canadian Dermatology Roundtable

The three approved IL-23 inhibitors — guselkumab, risankizumab, and tildrakizumab — have transformed the management of moderate-to-severe plaque psoriasis. Canadian Dermatology Today brought together Dr. Simon Nigen and Dr. Ajith Cy, moderated by Dr. Vimal Prajapati, to discuss practical strategies for managing difficult-to-treat psoriasis sites including the scalp, nails, and genitals; long-term outcomes and drug survival in real-world practice; and the emerging role of GLP-1 receptor agonists in addressing cardiometabolic comorbidities in patients with plaque psoriasis.